Platelets of 16 | Figure 1

neuroRN

Registered Nurse

Platelets of 16

Why you should join Figure 1

• Share your knowledge with our global community of healthcare professionals
• Get help from experts in your field
• Learn from our library of real-world cases and quizzes

Similar cases

Findings from the global AVA-PED-301 trial suggest avatrombopag may offer a safer, more convenient treatment option for children with chronic immune thrombocytopenia (ITP). In this randomized study of 75 patients aged 1–17, avatrombopag led to sustained platelet responses in 28% of participants vs. 0% with placebo. Over 80% of avatrombopag-treated patients met secondary platelet count goals. Mild side effects were most common, with no severe bleeding or thrombosis reported. With favorable safety and oral administration, avatrombopag may fill a key gap in pediatric ITP care.

Trending now

A 28-year-old woman presented with a 3-day history of intense pruritus over the lower back. She reported no recent travel or exposure to new environments. A 4-month-old male infant presented with skin lesions localized to the chin for the past 3 days. Physical examination revealed multiple small pustules with surrounding inflammatory signs on the chin.